Search - tctmd.com

Displaying 21 - 40 of 72

Sort: Relevancy | Date

Presentation TCT 2019

Preview From the Upcoming Ischemia Trial

Presenter: David Maron

September 27, 2019

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Shelley Wood

July 23, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Yael L. Maxwell

October 30, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

Presentation TCT 2018

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Presenter: E. Magnus Ohman, Stuart J. Pocock, David J. Maron

September 23, 2018

Presentation TCT 2018

CHIP in The Diabetic Patient: Special Considerations

Presenter: David J. Maron, Steven P. Marso, Cindy L. Grines

September 22, 2018

Presentation TCT 2018

Complete Revascularization is the Missing Link to Improve Diabetic PCI Outcomes

Presenter: David J. Maron, Steven P. Marso, Konstantinos Dean Boudoulas

September 22, 2018

Presentation TCT 2018

When is PCI a Valid Alternative To Only Medical Therapy or CABG in the Diabetic Patient?

Presenter: David J. Maron, Steven P. Marso, Sripal Bangalore

September 22, 2018

Presentation TCT 2018

Medical Therapy for Whom and When: What is the Ceiling of Medical Therapy?

Presenter: David J. Maron, Steven P. Marso, Norman E. Lepor

September 22, 2018

Presentation TCT 2018

Comprehensive CV Risk Reduction Strategy in Diabetics

Presenter: David J. Maron, Steven P. Marso, Kurt Huber

September 22, 2018

Presentation TCT 2018

Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact

Presenter: David J. Cohen, Sunil V. Rao, David J. Maron

September 22, 2018

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

Presentation TCT 2017

Case #2 Conclusion: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How We Treated

Presenter: David J. Maron, Alan C. Yeung, Vasim Farooq

November 01, 2017

Presentation TCT 2017

Case #3 Introduction: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Vasim Farooq

November 01, 2017

Presentation TCT 2017

Case #2 Introduction: An Asymptomatic Diabetic Patient With Normal Exercise Tolerance and Multivessel Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Frederick Feit

November 01, 2017

Presentation TCT 2017

Case #1 Conclusion: A Diabetic Patient With Left Main Disease How We Treated

Presenter: David J. Maron, Alan C. Yeung, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Case #1 Introduction: A Diabetic Patient With Left Main Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Should Pre-Diabetes Affect Revascularization Decisions?

Presenter: David J. Maron, Alan C. Yeung, Clemens von Birgelen

November 01, 2017

Presentation TCT 2017

Current State-of-the-Art Diabetes Medical Management and Novel Therapies in Clinical Trials

Presenter: David J. Maron, Alan C. Yeung, Michael E. Farkouh

November 01, 2017

Advertisement

Preview From the Upcoming Ischemia Trial

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

CHIP in The Diabetic Patient: Special Considerations

Complete Revascularization is the Missing Link to Improve Diabetic PCI Outcomes

When is PCI a Valid Alternative To Only Medical Therapy or CABG in the Diabetic Patient?

Medical Therapy for Whom and When: What is the Ceiling of Medical Therapy?

Comprehensive CV Risk Reduction Strategy in Diabetics

Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Case #2 Conclusion: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How We Treated

Case #3 Introduction: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How Should We Treat?

Case #2 Introduction: An Asymptomatic Diabetic Patient With Normal Exercise Tolerance and Multivessel Disease How Should We Treat?

Case #1 Conclusion: A Diabetic Patient With Left Main Disease How We Treated

Case #1 Introduction: A Diabetic Patient With Left Main Disease How Should We Treat?

Should Pre-Diabetes Affect Revascularization Decisions?

Current State-of-the-Art Diabetes Medical Management and Novel Therapies in Clinical Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content